Andrographis paniculata and Andrographolide - A Snapshot on Recent Advances in Nano Drug Delivery Systems against Cancer.

Cancer is one of the deadliest illnesses of the 21st century. Chemotherapy and radiation therapies both have considerable side effects. Antitumor antibiotics are one of them. Coughs, common colds, fevers, laryngitis, and infectious disorders have all been treated with Andrographis paniculata for centuries. Extracts of Andrographis effectively treat various ailments, as well as cancer. The most active molecule in Andrographis paniculata is andrographolide a, diterpene, and lactone. Andrographis paniculata and its derivatives have long been used to treat various ailments. Anti-inflammatory and cancerfighting characteristics have been observed in Andrographolide. Andrographolide, a diterpene lactone separated from Andrographis paniculata, has also been shown to have important criticalessential biological protective properties. It has also been suggested that it could be used to treat major human diseases like-rheumatoid like rheumatoid, colitis, and Parkinsons disease. This summary aims to highlight Andrographolide as a promising cancer treatment option. Several databases were searched for andrographolides cytotoxic/anti-cancer effects in pre-clinical and clinical research to serve this purpose. Several studies have shown that Andrographolide is helpful in cancer medication, as detailed in this review.

Advances in the Delivery of Cancer Therapeutics: A Comprehensive Review.

BACKGROUND: The effects of various chemotherapeutic agents have been assessed for their capacity to inhibit the cell replication in variety of cancer cases. At present there are more than hundred chemotherapeutic agents capturing worth 42 billion dollar of drug market. The major obstacle in the successful treatment of cancer is the obnoxious side effects of chemotherapeutics and multi drug resistance, which deteriorates the quality of life of cancer patient. OBJECTIVE: This article attempts to summarize different novel chemotherapeutic delivery systems which aim to circumvent these unwanted effects. Areas Covered: Outcomes of different tumor directed carrier systems have been discussed with special emphasis on nanocarriers systems, drug polymer conjugation, directly implantable matrices and others. In addition, combination therapy and immunotherapy are also discussed as a revolutionary alternative. CONCLUSION: Even though significant contributions have been made in the development of carrier systems for the chemotherapeutic agents, merits and demerits of all the avenues should be critically examined. Potential of all novel strategies should be exploited by critically evaluating their strength, weakness, opportunities and threats. Further, clinical trials based on revised and critically scrutinized frameworks and protocols are needed so that the efficiency and safe action of these new systems can be guaranteed in cancer patients.